PreveCeutical Engages Phoenix Corporate Finance Inc. to Provide Advisory Services
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has engaged Phoenix Corporate Finance Inc. to provide strategic and corporate advisory services for potential future transactions. Phoenix, based in Toronto, will advise on potential strategic transactions, including asset acquisitions or dispositions. As compensation, PreveCeutical will pay Phoenix $30,000 plus applicable taxes.
Stephen Van Deventer, Chairman and CEO of PreveCeutical, stated that as the company transitions from R&D to the clinical phase, they believe strategic partnerships and a new approach to their four research programs will be necessary. The company plans to allocate additional resources and talent to each program, specific to their respective medical fields.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ha affidato a Phoenix Corporate Finance Inc. la fornitura di servizi di consulenza strategica e aziendale per potenziali future transazioni. Phoenix, con sede a Toronto, consiglierà sulle possibili transazioni strategiche, comprese acquisizioni o cessioni di asset. Come compenso, PreveCeutical pagherà a Phoenix 30.000 dollari più le tasse applicabili.
Stephen Van Deventer, Presidente e CEO di PreveCeutical, ha dichiarato che mentre l'azienda passa dalla fase di ricerca e sviluppo a quella clinica, ritiene che siano necessarie partnership strategiche e un nuovo approccio ai loro quattro programmi di ricerca. L'azienda prevede di destinare ulteriori risorse e talenti a ciascun programma, specifici per i rispettivi campi medici.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ha contratado a Phoenix Corporate Finance Inc. para proporcionar servicios de asesoría estratégica y corporativa para futuras transacciones potenciales. Phoenix, con sede en Toronto, asesorará sobre posibles transacciones estratégicas, incluidas adquisiciones o disposiciones de activos. Como compensación, PreveCeutical pagará a Phoenix 30.000 dólares más los impuestos aplicables.
Stephen Van Deventer, Presidente y CEO de PreveCeutical, declaró que a medida que la empresa transita de I+D a la fase clínica, considera necesario establecer asociaciones estratégicas y un nuevo enfoque para sus cuatro programas de investigación. La empresa planea asignar recursos y talentos adicionales a cada programa, específicos para sus respectivos campos médicos.
프리베슈티컬 메디컬 주식회사 (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)는 피닉스 코퍼레이트 파이낸스 사에 잠재적인 미래 거래를 위한 전략 및 기업 자문 서비스를 제공하도록 의뢰했습니다. 토론토에 본사를 둔 피닉스는 자산 인수 또는 처분을 포함한 잠재적인 전략적 거래에 대해 자문할 것입니다. 보상으로 프리베슈티컬은 피닉스에게 30,000달러와 해당 세금을 지급할 것입니다.
프리베슈티컬의 chairman이자 CEO인 스티븐 반 드벤터는 회사가 R&D에서 임상 단계로 전환하는 과정에서 전략적 파트너십과 네 가지 연구 프로그램에 대한 새로운 접근 방식이 필요하다고 믿고 있다고 언급했습니다. 회사는 각 프로그램에 추가 자원과 인재를 배정할 예정입니다, 각 해당 의학 분야에 맞춰서.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) a engagé Phoenix Corporate Finance Inc. pour fournir des services de conseil stratégique et d'entreprise pour de potentielles futures transactions. Phoenix, basé à Toronto, conseillera sur d'éventuelles transactions stratégiques, y compris l'acquisition ou la cession d'actifs. En compensation, PreveCeutical paiera à Phoenix 30 000 dollars plus les taxes applicables.
Stephen Van Deventer, président et PDG de PreveCeutical, a déclaré qu'à mesure que l'entreprise passe de la recherche et développement à la phase clinique, ils estiment que des partenariats stratégiques et une nouvelle approche de leurs quatre programmes de recherche seront nécessaires. L'entreprise prévoit de réaffecter des ressources supplémentaires et des talents à chaque programme, spécifiques à leurs domaines médicaux respectifs.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) hat Phoenix Corporate Finance Inc. beauftragt, strategische und unternehmerische Beratungsdienste für potenzielle zukünftige Transaktionen bereitzustellen. Phoenix, mit Sitz in Toronto, wird zu potenziellen strategischen Transaktionen, einschließlich der Akquisition oder Veräußerung von Vermögenswerten, beraten. Als Vergütung wird PreveCeutical Phoenix 30.000 Dollar zuzüglich der anfallenden Steuern zahlen.
Stephen Van Deventer, Vorsitzender und CEO von PreveCeutical, erklärte, dass das Unternehmen, während es von F&E in die klinische Phase übergeht, glaubt, dass strategische Partnerschaften und ein neuer Ansatz für ihre vier Forschungsprogramme notwendig sein werden. Das Unternehmen plant, zusätzliche Ressourcen und Talente für jedes Programm bereitzustellen, die spezifisch für ihre jeweiligen medizinischen Bereiche sind.
- Engagement of Phoenix Corporate Finance Inc. for strategic advisory services
- Transition from R&D to clinical phase
- Plans to allocate additional resources to research programs
- Additional expense of $30,000 plus taxes for advisory services
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that it has engaged Toronto-based Phoenix Corporate Finance Inc. ("Phoenix") as its advisory firm to provide strategic and corporate advisory services relating to potential future transactions.
Pursuant to the engagement, Phoenix has agreed to provide corporate advisory services to the Company with respect to one or more potential strategic transactions, including the potential acquisition or disposition of assets. As consideration for the services, the Company has agreed to pay Phoenix an aggregate of
Mr. Stephen Van Deventer, Chairman and CEO commented, "As PreveCeutical transitions from R&D into the clinical phase, we believe moving forward will require strategic partnerships and an evolution as to how we approach each of our four research programs. Over the coming months we will dedicate additional resources and human talent to each of the different programs that are specific to the medical field of each therapy."
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About Phoenix Corporate Finance Inc.
Phoenix Corporate Finance Inc. is an independently owned mid-market corporate finance firm that serves the alternative and secondary funding requirements of Canadian-based companies. The objective of Phoenix is to position its client companies for the optimum number of financing options beyond what is available from banks and other financial institutions. Phoenix specializes in underwriting and procuring equity and debt funding from non-institutional and private capital sources. For more information regarding Phoenix's corporate, commercial, and ICI real estate financing activities, please visit: www.phoenixcorpfinance.ca.
On Behalf of the Board of Directors,
PreveCeutical Medical Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
ir@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding any potential acquisition or disposition transaction. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company may not execute on its proposed transaction plans and the Company determining that any proposed transaction is not an optimal strategy. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227133
FAQ
What advisory firm has PreveCeutical Medical Inc. (PRVCF) engaged?
What services will Phoenix Corporate Finance Inc. provide to PreveCeutical (PRVCF)?
How much will PreveCeutical (PRVCF) pay for Phoenix Corporate Finance Inc.'s services?
What transition is PreveCeutical Medical Inc. (PRVCF) currently undergoing?
